We rank companies based on fund manager, research analyst and news sentiment
ARWR stock icon

Arrowhead Research
ARWR

$23.92
7.12%
 

About: Arrowhead Pharmaceuticals Inc is an American biotechnology company. Its main target is the development of medicine to treat diseases with a genetic origin, characterized by the overproduction of one or more proteins. Its medical solutions are aimed at the genes that trigger the diseases. Its portfolio includes drugs targeting hepatitis B, Alpha-1 Antitrypsin Deficiency, thrombosis and angioedema, clear-cell and renal cell carcinoma, and cardiovascular disease.

Employees: 525

0
Funds holding %
of 6,474 funds
0
Analysts bullish %
of 9 analysts
0
News positive %
of 4 articles

Fund manager confidence

Based on 2023 Q4 SEC filings by fund managers ($100M+ AUM)

60% more call options, than puts

Call options by funds: $18.2M | Put options by funds: $11.4M

26% more first-time investments, than exits

New positions opened: 43 | Existing positions closed: 34

20% more capital invested

Capital invested by funds: $1.98B [Q3] → $2.37B (+$392M) [Q4]

4% more funds holding

Funds holding: 251 [Q3] → 260 (+9) [Q4]

3.43% more ownership

Funds ownership: 68.67% [Q3] → 72.09% (+3.43%) [Q4]

0% more funds holding in top 10

Funds holding in top 10: 4 [Q3] → 4 (+0) [Q4]

25% less repeat investments, than reductions

Existing positions increased: 73 | Existing positions reduced: 97

Research analyst outlook

9 Wall Street Analysts provided 1 year price forecasts over the past 6 months

Low target
$29
21%
upside
Avg. target
$46
92%
upside
High target
$90
276%
upside

9 analyst ratings

positive
67%
neutral
33%
negative
0%
HC Wainwright & Co.
Patrick Trucchio
276%upside
$90
Buy
Reiterated
8 Feb 2024
Citigroup
Shawn Egan
42%upside
$34
Neutral
Maintained
7 Feb 2024
RBC Capital
Luca Issi
109%upside
$50
Outperform
Reiterated
7 Feb 2024
Morgan Stanley
Michael Ulz
51%upside
$36
Equal-Weight
Maintained
7 Feb 2024
RBC Capital
Luca Issi
109%upside
$50
Outperform
Reiterated
16 Jan 2024

Financial journalist opinion

Based on 4 articles about ARWR published over the past 30 days